# SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05570825/  
OnCo record `nct05570825` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab in lung cancer, run by University of Washington, now recruiting.

## Summary

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT05570825 by University of Washington, with a registry enrolment figure of 30 participants, started 2023-04-06 and due to reach its primary completion in 2027-07-01. Interventions recorded: Biopsy; Biospecimen Collection; Computed Tomography; CXCR1/2 Inhibitor SX-682; Magnetic Resonance Imaging; Pembrolizumab; Positron Emission Tomography. Conditions listed: Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Best objective response rate. Lung eligibility wording from the registry: "* Pathologically or cytologically confirmed non-small cell lung cancer with no known oncogenic EGFR mutation, ALK rearrangement, ROS1 rearrangement or RET rearrangement". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05570825
- Phase: 2
- Setting: A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer
- Sponsor: University of Washington
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05570825: https://clinicaltrials.gov/study/NCT05570825

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05570825.json